Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,651
  • Shares Outstanding, K 34,008
  • Annual Sales, $ 103,460 K
  • Annual Income, $ -227,210 K
  • EBIT $ -60 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.51
  • Price/Sales 1.33
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 127.15% (+18.89%)
  • Historical Volatility 46.96%
  • IV Percentile 44%
  • IV Rank 12.24%
  • IV High 435.67% on 03/18/25
  • IV Low 84.12% on 08/04/25
  • Expected Move (DTE 12) 0.77 (19.47%)
  • Put/Call Vol Ratio 4.00
  • Today's Volume 20
  • Volume Avg (30-Day) 315
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 6,280
  • Open Int (30-Day) 12,113
  • Expected Range 3.17 to 4.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.29
  • Number of Estimates 2
  • High Estimate 1.54
  • Low Estimate 1.04
  • Prior Year -2.04
  • Growth Rate Est. (year over year) +163.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.70 +6.22%
on 11/07/25
4.69 -16.20%
on 11/10/25
+0.24 (+6.50%)
since 11/05/25
3-Month
3.63 +8.26%
on 11/05/25
5.20 -24.42%
on 09/10/25
-0.40 (-9.24%)
since 09/05/25
52-Week
1.38 +184.78%
on 04/07/25
7.34 -46.46%
on 07/11/25
+0.79 (+25.16%)
since 12/05/24

Most Recent Stories

More News
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET

AGEN : 3.93 (-3.20%)
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as ...

AGEN : 3.93 (-3.20%)
Agenus: Q3 Earnings Snapshot

Agenus: Q3 Earnings Snapshot

AGEN : 3.93 (-3.20%)
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in...

AGEN : 3.93 (-3.20%)
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market...

AGEN : 3.93 (-3.20%)
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastases Signals of tumor agnostic...

AGEN : 3.93 (-3.20%)
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Webcast on Tuesday, October 21, 2025 at 4:00 p.m. ET

AGEN : 3.93 (-3.20%)
Agenus Secures $10M Promissory Note with Zydus

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Agenus (...

AGEN : 3.93 (-3.20%)
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory...

AGEN : 3.93 (-3.20%)
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Agenus Inc . (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, taking place...

AGEN : 3.93 (-3.20%)

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 4.21
2nd Resistance Point 4.15
1st Resistance Point 4.04
Last Price 3.93
1st Support Level 3.87
2nd Support Level 3.81
3rd Support Level 3.70

See More

52-Week High 7.34
Fibonacci 61.8% 5.06
Fibonacci 50% 4.36
Last Price 3.93
Fibonacci 38.2% 3.66
52-Week Low 1.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar